Search
Regeneron Pharmaceuticals Inc
REGNAdd to Watchlist
742.120USD
+3.400+0.46%
Close 10-07 16:00（ET）
77.80BMarket Cap
17.47P/E TTM
TradingKey Chart
Intraday
1m
30m
1h
D
W
M
D
Today
+0.46%
5 Days
-2.13%
1 Month
-10.34%
6 Months
-2.13%
Year to Date
-3.48%
1 Year
+27.89%
Key Figures
738.050Open
753.680High
106.71KVolume
17.47P/E TTM
11.71P/E Dynamic
3.580Dividend TTM
0.10%Turnover Ratio
738.720Prev. Close
734.180Low
79.48MTurnover
17.64P/E Static
2.45P/B
0.48%Div Yield TTM
11.40%ROA
859.34052wk High
54.20Volume Ratio
4.41BNet Profit
104.84MShares
42.4810EPS TTM
0.26Beta
14.69%ROE
538.24052wk Low
3.59%Amplitude
84.22%Gross Margin
77.80BMarket Cap
10.99Reward/Risk
2.06%Risk Rate
Regeneron Pharmaceuticals Inc Stock (REGN) Moved Down by 10.44% on May 18: Facts Behind the Movement
• Key Phase 3 melanoma trial failed primary endpoint. • Analysts downgraded Regeneron stock and price targets. • Collaboration with Parabilis was overshadowed by trial failure.
TradingKeyMon, May 18
Regeneron Pharmaceuticals Inc Stock (REGN) Moved Down by 7.82% on Apr 29: Facts Behind the Movement
• Regeneron reported strong Q1 2026 financial results, exceeding expectations. • Eylea sales declined due to inventory and regulatory issues with syringe. • Experimental lung cancer drug combination will not advance to late-stage trials.
TradingKeyWed, Apr 29
Trump Strikes Again: Sends Warning Letter to Eli Lilly and Others, Drug Pricing Back in the Spotlight
TradingKey - On Thursday Eastern Time, U.S. President Donald Trump renewed pressure on the pharmaceutical industry by sending formal letters to several major drugmakers
TradingKeyJul 31, 2025
Regeneron Pharmaceuticals Inc's Score
0.01vs previous score
Forecast7.73
Financial Health9.07
Technical3.24
Valuation Dimensions8.55
Institutional Confidence10.00
Risk Assessment8.68
Media Coverage
Coverage Level
Very Low
Very High
Positive+
Analyst Rating
Regeneron Pharmaceuticals Inc Technical Analysis
Technical Indicators
Sell
Summary
Neutral
Moving Average
Neutral
Financial Indicators
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
Earnings
Next reporting date
--
Reporting Period
2026Q2
Earnings / Forecast
12.62/10.26
Revenue / Forecast
4.29B/3.82B
Regeneron Pharmaceuticals Inc Profile
SectorPharmaceuticals
Ticker SymbolREGN
Number of employees15106
CountryUnited States of America
Ownership
| Shareholders | Proportion |
|---|---|
| Vanguard Capital Management, LLC | 6.46% |
| BlackRock Institutional Trust Company, N.A. | 5.27% |
| State Street Investment Management (US) | 4.52% |
| Dodge & Cox | 4.46% |
| Shareholder Types | Proportion |
|---|---|
| Investment Advisor | 47.12% |
| Investment Advisor/Hedge Fund | 32.63% |
| Hedge Fund | 3.44% |
| Research Firm | 2.77% |
Related Instruments
+2.70%
+1.44%
+1.75%
+0.60%
+1.77%
+0.95%
+2.60%
+1.82%
+1.95%
+1.82%
+0.66%
+0.18%
-1.23%
+1.62%
+0.90%
+4.81%
+1.49%
-0.22%
-0.55%
FAQs
What is the current price of Regeneron Pharmaceuticals Inc (REGN)?
The current price of Regeneron Pharmaceuticals Inc (REGN) is 742.12.
What is the symbol of Regeneron Pharmaceuticals Inc?
The ticker symbol of Regeneron Pharmaceuticals Inc is REGN.
What is the 52-week high of Regeneron Pharmaceuticals Inc?
The 52-week high of Regeneron Pharmaceuticals Inc is 859.34.
What is the 52-week low of Regeneron Pharmaceuticals Inc?
The 52-week low of Regeneron Pharmaceuticals Inc is 538.24.
What is the market capitalization of Regeneron Pharmaceuticals Inc?
The market capitalization of Regeneron Pharmaceuticals Inc is 77.80B.
Is Regeneron Pharmaceuticals Inc (REGN) currently rated as Buy, Hold, or Sell?
According to analysts, Regeneron Pharmaceuticals Inc (REGN) has an overall rating of Buy, with a price target of 852.45.
What is the Earnings Per Share (EPS TTM) of Regeneron Pharmaceuticals Inc (REGN)?
The Earnings Per Share (EPS TTM) of Regeneron Pharmaceuticals Inc (REGN) is 42.48.